- Glenn Hearson
Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Asthma
Updated: Sep 5, 2022
We are currently undertaking research into a potential new treatment for airway inflammation in adults with inadequately controlled asthma with AstraZeneca,
What is the purpose of this study?
This study is being carried out to examine the effect of tezepelumab (Study Drug) on inflammation, understanding how the study drug works and correlates with your asthma signs and symptoms.
Asthma is a lung disease associated with inflammation (swelling) or the airways. Certain proteins made by the body, called cytokines, are thought to be important in causing inflammation. One of these cytokines, called cytokine thymic stromal lymphopoietin (TSLP), appears to play a major role in asthma.
Other proteins, called antibodies are usually produced by your body to find and inactivate specific substances that enter your body such as bacteria, fungi, viruses and others (called antigens).
Tezepelumab is a laboratory-made antibody that binds and blocks the effect of TSLP. It may help decrease airway inflammation. Tezepelumab is still experimental and not yet approved for Adult Participation Information general use anywhere. Early studies show that tezepelumab appears to improve asthma control in patients with moderate to severe asthma.
Study Principal Investigator; Professor Tim Harrison
This study is now fully completed